

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYDARCBDF

(Page 1 of 3)

DOCTOR'S ORDERS Htcm Wt	kg	BSA	m²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form				
DATE: To be given: Cyc	le #:			
Date of Previous Cycle:				
****Ensure Red Blood Cell Phenotype and Group and Screen for all patients prior to Cycle 1 Delay treatment week(s) CBC & Diff, Platelets day of treatment				
Proceed with all medications for entire cycle as written, if within 96 hours of Day 1: ANC greater than or equal to 1.0 x 10 ⁹ /L, platelets greater than or equal to 50 x 10 ⁹ /L, total bilirubin less than or equal to 1.5 x upper limit of normal, and eGFR or creatinine clearance per protocol				
Dose modification for: Hematology: Other Toxicity:				
Proceed with treatment based on blood work from				
CYCLOPHOSPHAMIDE – Cycles 1 to 6				
cyclophosphamide 500 mg PO once weekly in the morning on Days 1, 8, 15 and 22 OR	. Dispen	ise	cycles.	
cyclophosphamide mg PO once weekly in the morning on Days OR	Dis	pense	cycles.	
cyclophosphamide 50 mg PO once in the morning every 2 days for doses.	Dispense	e c	ycles	
BORTEZOMIB – Cycles 1 to 6 • Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily bortezomib ☐ 1.5 mg/m² ☐ 1.3 mg/m² or ☐ 1 mg/m² or ☐ 0.7 mg/m² or ☐ 0.5 mg/m² (select one) x BSA = mg subcutaneous injection weekly on Days 1, 8, 15, and 22				
STEROID (select one)* RN to use patient's therapeutic steroid as pre-med for darate	ımumab)		
Cycles 1 to 6				
☐ dexamethasone ☐ 40 mg or ☐ 20 mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, <i>OR</i>				
dexamethasonemg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, <i>OR</i>				
predniSONEmg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning				
☐ No steroid				
*Refer to Protocol for suggested dosing options				
DOCTOR'S SIGNATURE:	SIGN	ATURE:		
	UC:			



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYDARCBDF

(Page 2 of 3)

DATE:				
Have Hypersensitivity Reaction Tray and Protocol Available				
Insert a peripheral IV and saline lock for Cycle 1 Day 1 only for use in the event of	of a hypersensitivity reaction.			
DARATUMUMAB				
Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily				
DARATUMUMAB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm.				
dexamethasone as ordered in steroid section				
montelukast 10 mg PO prior to daratumumab on Cycle 1 Day 1				
montelukast 10 mg PO prior to each daratumumab				
acetaminophen 650 mg PO prior to each daratumumab. Repeat acetaminophen 65 needed	0 mg PO every 4 hours when			
Select one of the following:				
I loratadine 10 mg PO prior to each daratumumab, then diphenhydrAMINE 50 mg	J IV every 4 hours when needed			
OR The second of				
☐ diphenhydrAMINE 50 mg ☐ PO or ☐ IV prior to each daratumumab. Repeat dip hours when needed	ohennydramine 50 mg IV every 4			
DARATUMUMAB				
□ CYCLE 1, Days 1, 8, 15 and 22: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes* □ CYCLE 2, Days 1, 8, 15 and 22: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes* □ CYCLES 3 to 6, Days 1 and 15: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes* □ CYCLES 7 onwards, Day 1: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*				
	x cycle(s) (max 3 cycles)			
*Observe patient for 1 hour after administration on Day 1 of Cycle 1 only. For patients switching from IV daratumumab, observe for 30 minutes after the first subcutaneous dose. Observation not required on subsequent doses unless requested by physician. Vital signs immediately prior to and at the end of injection, and at end of observation period of first injection only, and as needed.				
NB: During treatment with subcutaneous daratumumab, administer other subcutaneous drugs at al possible.	ternative injection sites whenever			
DOCTOR'S SIGNATURE:	SIGNATURE:			
	UC:			



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care.

PROTOCOL CODE: LYDARCBDF

(Page 3 of 3)

DATE:			
RETURN APPOINTMENT ORDERS			
For Cycles 1 to 6 book chemo on Days 1, 8, 15, 22 For Cycles 7 and subsequent, book chemo on Day 1 Return in four weeks for Doctor and Cycle Return in eight weeks for Doctor and Cycles and Book chemo x 2 cycles. Return in twelve weeks for Doctor and Cycles, and Book chemo x 3 cycles Last Cycle. Return in week(s).			
CBC & Diff, platelets, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, beta-2 microglobulin, LDH, random glucose, serum protein electrophoresis and serum free light chain levels, troponin I cardiac high sensitivity, NT-pro BNP, albumin creatinine ratio urine every 4 weeks Urine protein electrophoresis every 4 weeks Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks CBC & Diff, platelets Days 8, 15, 22 Creatinine, sodium, potassium Days 8, 15, 22 Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22 Random glucose Days 8, 15, 22 Calcium, albumin Days 8, 15, 22 Other tests: Consults: See general orders sheet for additional requests			
DOCTOR'S SIGNATURE:	SIGNATURE:		
	uc:		